Combination Therapy

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

By

Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.

AntiCancer, Rheumatoid Arthritis Drug Combination Produced Synergistic Attack on Tumor Cells

AntiCancer, Rheumatoid Arthritis Drug Combination Produced Synergistic Attack on Tumor Cells

By

The combination of an anticancer agent with a rheumatoid arthritis medication results in synergistic effect that improves the efficacy of the anticancer agent.

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

By

Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.

Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly

Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly

By

The addition of temozolomide to short-course radiotherapy in elderly patients with glioblastoma was associated with some survival benefit compared with radiotherapy alone.

Single Chemotherapy Dose Informs Treatment Strategy for Advanced Laryngeal Cancer

Single Chemotherapy Dose Informs Treatment Strategy for Advanced Laryngeal Cancer

By

A new approach in which patients receive a single dose of chemotherapy may greatly improve the laryngeal cancer survival rate.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

By

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

By

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

By

Results are presented from the phase 3 ENDEAVOR trial, which demonstrated the effect of carfilzomib plus dexamethasone (Kd) vs bortezomib plus dexamathasone (Vd) on risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

Topical Combination Reduces Actinic Keratosis Lesions, Reducing Risk of Squamous Cell Carcinoma

Topical Combination Reduces Actinic Keratosis Lesions, Reducing Risk of Squamous Cell Carcinoma

By

Study investigates the effectiveness of a topical treatment with an immune system-activator and a topical chemotherapy on actinic keratosis, a precursor to squamous cell carcinoma.

BRd Safe, Efficacious as Second-line Treatment for R/R Myeloma

BRd Safe, Efficacious as Second-line Treatment for R/R Myeloma

By

The combination of bendamustine, lenalidomide, and dexamethasone was highly active as second-line treatment for relapsed/refractory multiple myeloma.

Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas

By

In a phase 1 clinical trial, the combination produces a significant and long-lasting response in patients with advanced disease including metastases to the peritoneum and lung.

Panobinostat, Bortezomib, Thalidomide Efficacious in Relapsed Myeloma

By

In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.

Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma

By

The US FDA granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin for the treatment of certain patients with soft tissue sarcoma.

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

By

Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC

By

The combination of adjuvant bevacizumab and capecitabine failed to improve disease-free survival compared with capecitabine alone in patients with mCRC who had undergone potentially curative surgery.

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

By

Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

By

The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).

Chemoradiation Combination Could Preserve Larynx in Patients With Laryngeal and Hypolaryngeal Cancer

Chemoradiation Combination Could Preserve Larynx in Patients With Laryngeal and Hypolaryngeal Cancer

By

Researchers assessed the rates of laryngeal preservation and laryngectomy-free survival in patients with laryngeal or hypopharyngeal cancer who received the monoclonal antibody cetuximab and radiation therapy or radiation therapy alone.

Immunotherapy Combination is Effective in Colorectal Cancer

By

Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).

Novel Nanoparticle Achieves Concomitant Tumor Cell Death and Resistance Suppression

By

Resistance to therapy through adaptation poses a major hurdle for cancer therapy. Bioengineers addressed this by creating a single nanoparticle that comprises a synergistic drug pair that shuts down mechanisms of resistance to a degree that has not been previously achieved.

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

By

Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.

Disease-Free Status Is Achieved by Combining Immunotherapy Treatments in Patient With Metastatic Melanoma

By

A patient with refractory metastatic melanoma was successfully treated with a novel combination of 2 different types of immunotherapy.

Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma

By

Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.

Novel Approach Uses Ultrasound to Enhance Efficacy of Chemotherapy in Pancreatic Cancer

Novel Approach Uses Ultrasound to Enhance Efficacy of Chemotherapy in Pancreatic Cancer

By

Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.

Chemotherapy and Radiation Prior to Surgery Improves Outcomes in Patients With Pancreatic Cancer

Chemotherapy and Radiation Prior to Surgery Improves Outcomes in Patients With Pancreatic Cancer

By

Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.

Adjuvant Gemcitabine/Capecitabine: New Standard of Care for Resected Pancreatic Cancer

Adjuvant Gemcitabine/Capecitabine: New Standard of Care for Resected Pancreatic Cancer

By

Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

By

In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.

Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma

Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma

By

Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

By

When added to the CHOP regimen, alemtuzumab increases remission rates in elderly patients with peripheral T cell lymphoma, final analysis of the international ACT-2 phase 3 trial presented at the ASCO 2016 Annual Meeting has shown.

Nimotuzumab + Radiotherapy Less Toxic Than Cisplatin + Radiotherapy for Stage III/IVB Nasopharyngeal Cancer

Nimotuzumab + Radiotherapy Less Toxic Than Cisplatin + Radiotherapy for Stage III/IVB Nasopharyngeal Cancer

By

Patients with locally advanced nasopharyngeal cancer concurrently treated with nimotuzumab and radiotherapy had similar rates of progression-free and overall survival to those treated with cisplatin and radiotherapy, but with significantly fewer GI and hematologic toxicities, according to phase 3 trial results presented at the ASCO 2016 Annual Meeting.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs